Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications

Cancer Treat Res Commun. 2023:37:100779. doi: 10.1016/j.ctarc.2023.100779. Epub 2023 Nov 17.


Bladder cancer researchers and clinicians have increasingly viewed tumor biology through the lens of genomic and molecular alterations, drastically improving our knowledge of the underlying disease biology. This understanding has led to significant advances in treatment options that allow implementation of a personalized approach to cancer treatment. Large-scale genomic studies initially focused on the most common forms of bladder cancer. However, as genomic and molecular technologies become more widespread and are applied to less common variant histologies, we are gaining additional insight into the unique molecular and genomic characteristics driving the biology of variant histologies of bladder cancer. In this review, we summarize the current state of knowledge of molecular alterations underlying the distinct tumor biology of plasmacytoid urothelial carcinoma and how these alterations may impact treatment options.

Keywords: Bladder cancer; Molecular characterization; Plasmacytoid; Urothelial carcinoma.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Carcinoma, Transitional Cell* / drug therapy
  • Carcinoma, Transitional Cell* / genetics
  • Carcinoma, Transitional Cell* / pathology
  • Genomics
  • Humans
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / genetics
  • Urinary Bladder Neoplasms* / pathology